United-Guardian, Inc. — Q2 2012 Form 10-Q
Business and period: The company develops, manufactures, and markets cosmetic and personal-care ingredients, pharmaceutical and medical products, and specialty industrial products. This unaudited report covers the three and six months ended June 30, 2012, compared with the same periods in 2011.
Financial results
| Metric | Q2 2012 | Q2 2011 | First half 2012 | First half 2011 |
|---|---|---|---|---|
| Net sales | $3.735 million | $4.060 million | $7.624 million | $7.702 million |
| Income from operations | $1.722 million | $1.731 million | $3.468 million | $3.392 million |
| Net income | $1.193 million | $1.225 million | $2.422 million | $2.391 million |
| Basic and diluted EPS | $0.26 | $0.27 | $0.53 | $0.52 |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $2.788 million | $2.931 million |
- Q2 sales fell 8.0% year over year; first-half sales fell 1.0%. Q2 net income declined 2.6%, while first-half net income rose 1.3%.
- Gross margin was approximately 60.8% in Q2 and 60.6% for the first half, compared with 59.9% in both prior-year periods. Operating margin was approximately 46.1% and 45.5%, respectively, versus 42.6% and 44.0%.
- First-half operating cash flow decreased about 4.9%. Investing activities used $112,101 and financing activities used $1.931 million, principally for dividends. Cash increased $745,140 to $1.836 million.
- At June 30, cash and cash equivalents were $1.836 million and marketable securities were $9.474 million. Working capital was $13.603 million, and the current ratio was 11.99:1. Total liabilities were approximately $1.360 million; the balance sheet reports no debt.
- First-half dividends paid were $1.931 million, or $0.42 per share, versus $1.655 million, or $0.36 per share, in 2011. Capital spending was $70,634.
Material changes and management commentary
- The principal sales pressure was RENACIDIN, which accounts for about 85% of pharmaceutical sales. A production disruption at the third-party manufacturer began in May 2012 and constrained shipments; pharmaceutical sales fell 46.6% in Q2. The prior-year quarter had unusually strong RENACIDIN orders following an earlier shortage and ahead of a price increase.
- At the report date, the company said its RENACIDIN inventory was depleted and it could not fill further orders until production resumed or held product batches were released. The supplier was holding three batches produced in May, pending resumption of regular production. The supplier hoped to restart in September 2012, subject to FDA approval and other potential delays. Failure to receive product before the end of September could significantly affect Q3 pharmaceutical sales.
- The supplier also notified the company it would stop supplying product after January 2014. Management was seeking a replacement manufacturer and planned to build additional inventory if needed during the transition. The company said it would seek reimbursement from the supplier for losses related to the disruption.
- Personal-care sales declined 2.6% in Q2 but increased 1.2% for the first half, which management attributed primarily to normal order timing at Ashland Specialty Ingredients, its largest marketing partner. Medical-product sales rose 31.0% in Q2 but declined 4.5% for the first half, reflecting customer ordering patterns.
- Management attributed lower cost-of-sales ratios to reduced utility and insurance costs and a more favorable product mix. Lower professional, consulting, legal, accounting, payroll-related, and insurance expenses reduced operating expenses.
- Management stated that working capital should support operations for at least 12 months and expected no significant capital expenditures for the remainder of 2012. No specific earnings or revenue guidance was provided.
Risks, contingencies, and other disclosures
- Key stated risks include product competition and acceptance, product quality, ability to develop new products, intellectual-property changes, economic and industry conditions, regulatory changes, and financial-market conditions.
- Receivables averaged 44 days outstanding in the first half, up from 33 days in 2011. Management cited an increase in receivables as a factor in working-capital growth.
- Marketable securities are available-for-sale investments measured at fair value using Level 1 quoted prices. Investment income declined 42.5% in Q2 and 22.6% for the first half.
- The company reported no legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective; no material changes in internal control over financial reporting were reported.
Important facts for investors to verify
- Whether the supplier resumed production, obtained required FDA approval, and released the three held batches; confirm the actual effect on Q3 sales and order fulfillment.
- Progress toward qualifying a replacement RENACIDIN manufacturer before the January 2014 supply cutoff, including transition timing and any planned inventory build.
- The extent of customer and channel concentration, particularly dependence on RENACIDIN supply and Ashland Specialty Ingredients, and whether order timing explains personal-care sales movements.
- Whether receivables collection times return toward prior levels and whether working capital and cash generation remain adequate alongside dividend payments.